Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|16|3043-3051

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.16, 2013-08, pp. : 3043-3051

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The ErbB2 Signaling Network as a Target for Breast Cancer Therapy

By Badache Ali   Gonçalves Anthony  

Journal of Mammary Gland Biology and Neoplasia, Vol. 11, Iss. 1, 2006-01 ,pp. : 13-25

Springer Publishing Company

Access to resources Recommend Favorite

In vivo evidence supporting a metastasis suppressor role for Stard13 (Dlc2) in ErbB2 (Neu) oncogene induced mouse mammary tumors

By  

GENES, CHROMOSOMES AND CANCER, Vol. 57, Iss. 4, 2018-04 ,pp. : 182-191

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Phase I Clinical Trial of Topotecan Given Every 2 Weeks in Patients with Refractory Solid Tumors

By  

Oncology, Vol. 61, Iss. 4, 2001-11 ,pp. : 265-270

Karger

Access to resources Recommend Favorite

Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 9, 2015-09 ,pp. : 1562-1566

John Wiley & Sons Inc

Access to resources Recommend Favorite

Loss of ErbB2 Expression in Pulmonary Metastatic Lesions in Osteosarcoma

By  

Oncology, Vol. 60, Iss. 4, 2001-06 ,pp. : 361-366

Karger

Access to resources Recommend Favorite